Table 2.
Univariate Analyses of Virologic Response to Treatment-Change Episodes as a Function of Demographic Factors, Baseline Disease Factors, and Salvage Therapy
| Variable | Nonresponders (n = 259) |
Responders (n = 475) |
P a |
|---|---|---|---|
| Characteristic of treatment history | |||
|
| |||
| ARV therapy, years | 5 (3–7) | 5 (3–7) | .3 |
|
| |||
| ARVs, no. | 6 (4–8) | 5 (3–7) | <.001 |
|
| |||
| ARV regimens, no. | 4 (2–6) | 3 (1–4) | <.001 |
|
| |||
| Non-HAART regimens, no. | 2 (1–3) | 1 (0–3) | <.001 |
|
| |||
| Protease inhibitors, no. | 2 (1–3) | 1 (1–2) | <.001 |
|
| |||
| NRTIs, no. | 4 (2–4) | 3 (2–4) | .006 |
|
| |||
| NNRTIs, no. | 1 (0–1) | 0 (0–1) | <.001 |
|
| |||
| ARV classes, no. | 3 (2–3) | 2 (2–3) | <.001 |
|
| |||
| Year ARV therapy begun | 1996 (1994–1997) | 1996 (1994–1998) | <.001 |
|
| |||
| Previous HIV-1 RNA BLQ, % | 20.1 | 41.3 | <.001b |
|
| |||
| Patient characteristic at baseline | |||
|
| |||
| Age, years | 42 (38–49) | 45 (39–51) | .009 |
|
| |||
| Female sex, % | 7.7 | 8.2 | .03b |
|
| |||
| HIV-1 RNA, log copies/mL | 4.4 (4–4.9) | 4.1 (3.6–4.6) | <.001 |
|
| |||
| CD4 cell count, cells/mL | 190 (94.5–327) | 283 (175–407.5) | <.001 |
|
| |||
| Characteristic of salvage regimen | |||
|
| |||
| ARVs, no. | 3 (3–4) | 3 (3–4) | .01 |
|
| |||
| Previously unused ARVs, no. | 1 (1–2) | 2 (1–2) | <.001 |
|
| |||
| Previously unused ARV classes, no. | 0 (0–1) | 1 (0–1) | <.001 |
|
| |||
| Year of treatment-change episode | 2000 (1999–2002) | 2001 (2000–2003) | <.001 |
|
| |||
| Unweighted rGSSc | |||
|
| |||
| ANRS | 2 (1–3) | 3 (2–3) | <.001 |
|
| |||
| HIVdb | 1.5 (0.75–2.25) | 2.25 (1.5–2.75) | <.001 |
|
| |||
| Rega | 2 (1–2.5) | 2.5 (2–3) | <.001 |
|
| |||
| ViroSeq | 1.5 (1–2.5) | 2.5 (2–3) | <.001 |
NOTE. Except for categorical data, given as percentages, data are given as medians, with interquartile ranges in parentheses. ANRS, Agence National de Recerche sur le SIDA; ARV, antiretroviral; BLQ, below the limit of quantification (<75 copies/mL; Versant branched DNA assay); HAART, highly active antiretroviral therapy; HIV-1, human immunodeficiency virus type 1; HIVdb, HIV Drug Resistance Database; NRTIs, nucleoside reverse-transcriptase (RT) inhibitors; NNRTIs, nonnucleoside RT inhibitors; rGSS, regimen-specific genotypic susceptibility score.
Student’s t test was used for all comparisons, except as indicated for categorical data.
Comparisons by χ2 test.
Algorithm versions were as follows: ANRS 2007.10, HIVdb 4.3.1, Rega 7.1.1, and ViroSeq 2.8.